查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611859

陰道炎治療藥物市場：按藥物類型、給藥方式、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年陰道炎治療藥物市場價值為26億美元，預計到2024年將達到27.6億美元，複合年成長率為8.75%，到2030年將達到46.8億美元。

陰道炎治療市場包括陰道炎治療方法的開發、生產和分銷，發炎。細菌性陰道炎、酵母菌感染疾病和滴蟲性陰道炎的流行凸顯了對有效治療方法的需求，這些都是全世界陰道炎的主要原因。主要用途包括抗生素和抗真菌藥物等處方藥，以及用於緩解症狀和控制感染的非處方藥。最終使用領域主要是醫療機構和藥房，解決慢性和急性疾病。推動市場成長的因素包括女性生殖健康意識的提高、各種生活方式因素導致的感染疾病率的增加以及診斷技術的進步。新療法和組合的推出為市場參與企業提供了擴大其投資組合的潛在機會。此外，女性健康領域研究經費的增加正在為新型生技藥品和標靶治療鋪平道路。然而，挑戰包括嚴格的監管核准、需要進行全面的臨床試驗以確保療效和安全性，以及當前療法可能抑制患者依從性的潛在副作用。新興市場也受到限制獲得醫療保健的社會經濟因素的影響。創新應著重於開發更有效、見效快且副作用最小的治療方法，包括利用生物技術的進步，例如基於微生物的治療方法和個體化醫療。我們可以透過投資早期檢測和預防的研究、擴大與大學和生物技術公司的合作夥伴關係以及推動治療方案的前沿來發展我們的業務。競爭格局仍然分散，既有成熟的製藥公司，也有新興的新興企業，顯示競爭格局充滿活力，具有巨大的創新和擴張空間。

主要市場統計
基準年[2023] 26億美元
預測年份 [2024] 27.6億美元
預測年份 [2030] 46.8億美元
複合年成長率（%） 8.75%

市場動態：快速發展的陰道炎治療市場的關鍵市場洞察

供需的動態交互作用正在改變陰道炎藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於感染疾病導致陰道炎的盛行率增加
    • 人們越來越意識到性健康如何影響女性
    • 人們越來越偏好微創醫療程序和先進的陰道產品
  • 市場限制因素
    • 治療陰道炎的高成本
  • 市場機會
    • 治療陰道感染疾病的診斷和治療藥物的技術進步
    • 對用於治療陰道炎的凝膠和乳膏等標靶給藥系統的需求
  • 市場挑戰
    • 與使用陰道炎藥物相關的副作用

波特五力：駕馭陰道炎藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解陰道炎治療藥物市場的外部影響

外部宏觀環境因素在塑造陰道炎治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解陰道炎治療藥物市場的競爭狀況

對陰道炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣陰道炎治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估陰道炎治療藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪陰道炎治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對陰道炎治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於感染疾病導致陰道炎的發生率增加
      • 提高人們對性健康如何影響女性的認知
      • 人們對微創醫療程序和先進的陰道產品越來越感興趣。
    • 抑制因素
      • 治療陰道炎費用高
    • 機會
      • 陰道感染疾病診斷和治療的技術進步
      • 對用於治療陰道炎的凝膠和乳膏等標靶給藥系統的需求
    • 任務
      • 與使用陰道炎藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按類型分類的陰道炎治療藥物市場

  • 抗菌的
  • 抗真菌劑
  • 荷爾蒙

第7章陰道炎治療藥物市場：透過提供

  • 店面銷售(OTC)
  • 處方箋

第8章陰道炎治療藥物市場：依給藥途徑

  • 口服
  • 話題

第9章陰道炎治療藥物市場：依分銷管道分類

  • 醫院
  • 藥局
    • 離線
    • 線上

第10章 北美及南美陰道炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章：亞太地區陰道炎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲陰道炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Ltd.
  • Dare Bioscience, Inc.
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Enzo Biochem Inc.
  • Janssen Pharmaceuticals Inc.
  • Lumavita AG
  • Lupin Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Mission Pharmacal Company
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Perrigo Company plc
  • Pfizer Inc.
  • PhagoMed Biopharma GmbH
  • Sanofi SA
  • Starpharma Holdings Limited
  • Sun Pharmaceutical Industries Limited
  • TenNor Therapeutics Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Pharmaceuticals, Inc.
Product Code: MRR-8E22B61932BA

The Vaginitis Therapeutics Market was valued at USD 2.60 billion in 2023, expected to reach USD 2.76 billion in 2024, and is projected to grow at a CAGR of 8.75%, to USD 4.68 billion by 2030.

The vaginitis therapeutics market encompasses the development, production, and distribution of treatments for vaginitis, an inflammation of the vagina characterized by symptoms such as itching, discomfort, and discharge. The necessity for effective therapies is underscored by the prevalence of bacterial vaginosis, yeast infections, and trichomoniasis, which are leading causes of vaginitis worldwide. Key applications include prescription medications like antibiotics and antifungals, as well as over-the-counter products aimed at symptom relief and infection management. End-use sectors predominantly involve healthcare facilities and pharmacies, servicing both chronic and acute conditions. The market's growth drivers include increased awareness about female reproductive health, rising incidences of infections due to various lifestyle factors, and advancements in diagnostic techniques. The launch of new therapeutics and combination treatments presents potential opportunities for market players to expand their portfolios. Additionally, increased funding in women's health research is paving the way for novel biologics and targeted therapies. However, challenges include stringent regulatory approvals, the need for comprehensive clinical trials to ensure efficacy and safety, and the potential side effects of current therapies which can hinder patient compliance. The market is also affected by socio-economic factors that limit access to healthcare in developing regions. Innovation should focus on developing more effective, faster-acting treatments with minimal side effects, possibly leveraging biotechnological advances such as microbiome-based therapies and customized medicine. Business growth can be found in investing in research for early detection and prevention approaches, and expanding partnerships with universities and biotech companies to push the frontier of treatment options. The competitive landscape remains fragmented, with a mix of established pharmaceutical companies and emerging start-ups, suggesting a dynamic nature with substantial room for innovation and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.60 billion
Estimated Year [2024] USD 2.76 billion
Forecast Year [2030] USD 4.68 billion
CAGR (%) 8.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of vaginitis caused by infections
    • Increasing awareness about the impacts of sexual health on women
    • Growing preference for minimally invasive medical procedures and advanced vaginal products
  • Market Restraints
    • High cost associated with the treatment of vaginitis
  • Market Opportunities
    • Technological advancement in diagnostics and therapeutics for treating vaginal infections
    • Demand for targeted delivery systems such as gels and creams for treating vaginitis
  • Market Challenges
    • Side effects associated with the use of vaginitis medications

Porter's Five Forces: A Strategic Tool for Navigating the Vaginitis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaginitis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaginitis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaginitis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaginitis Therapeutics Market

A detailed market share analysis in the Vaginitis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaginitis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaginitis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaginitis Therapeutics Market

A strategic analysis of the Vaginitis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaginitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dare Bioscience, Inc., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, Enzo Biochem Inc., Janssen Pharmaceuticals Inc., Lumavita AG, Lupin Pharmaceuticals Inc., Merck & Co., Inc., Mission Pharmacal Company, Mylan NV, Novartis AG, Novo Nordisk A/S, Perrigo Company plc, Pfizer Inc., PhagoMed Biopharma GmbH, Sanofi S.A., Starpharma Holdings Limited, Sun Pharmaceutical Industries Limited, TenNor Therapeutics Ltd, Teva Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Vaginitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-bacterial, Anti-fungal, and Hormone.
  • Based on Offering, market is studied across Over-The-Counter (OTC) and Prescription.
  • Based on Route of Administration, market is studied across Oral and Topical.
  • Based on Distribution Channel, market is studied across Hospital and Pharmacies. The Pharmacies is further studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of vaginitis caused by infections
      • 5.1.1.2. Increasing awareness about the impacts of sexual health on women
      • 5.1.1.3. Growing preference for minimally invasive medical procedures and advanced vaginal products
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of vaginitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics and therapeutics for treating vaginal infections
      • 5.1.3.2. Demand for targeted delivery systems such as gels and creams for treating vaginitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the use of vaginitis medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaginitis Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-bacterial
  • 6.3. Anti-fungal
  • 6.4. Hormone

7. Vaginitis Therapeutics Market, by Offering

  • 7.1. Introduction
  • 7.2. Over-The-Counter (OTC)
  • 7.3. Prescription

8. Vaginitis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Vaginitis Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Pharmacies
    • 9.3.1. Offline
    • 9.3.2. Online

10. Americas Vaginitis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaginitis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaginitis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch Health Companies Inc.
  • 3. Bayer AG
  • 4. Cipla Ltd.
  • 5. Dare Bioscience, Inc.
  • 6. Dr Reddy's Laboratories Ltd
  • 7. Eli Lilly and Company
  • 8. Enzo Biochem Inc.
  • 9. Janssen Pharmaceuticals Inc.
  • 10. Lumavita AG
  • 11. Lupin Pharmaceuticals Inc.
  • 12. Merck & Co., Inc.
  • 13. Mission Pharmacal Company
  • 14. Mylan NV
  • 15. Novartis AG
  • 16. Novo Nordisk A/S
  • 17. Perrigo Company plc
  • 18. Pfizer Inc.
  • 19. PhagoMed Biopharma GmbH
  • 20. Sanofi S.A.
  • 21. Starpharma Holdings Limited
  • 22. Sun Pharmaceutical Industries Limited
  • 23. TenNor Therapeutics Ltd
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Tolmar Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VAGINITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VAGINITIS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-FUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 232. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023